89results about How to "Improve ejection fraction" patented technology

This invention is directed to a partitioning device for separating a patient's heart chamber into a productive portion and a non-productive portion. The device is particularly suitable for treating patients with congestive heart failure. The partitioning device has a frame-reinforced, expandable membrane which separates the productive and non-productive portions of the heart chamber. The proximal ends of the ribs of the frame have tissue penetrating elements about the periphery thereof which are configured to penetrate tissue lining the heart wall at an angle approximately perpendicular to a longitudinal axis of the partitioning device. The partitioning device has a hub with a non-traumatic distal end to engage the ventricular wall.

A method and device for the treatment of a patient with heart disease and particularly a heart chamber having a myocardial rupture or characteristics of an incipient myocardial rupture. The heart chamber is partitioned so as to isolate a non-productive portion having a rupture or a region of an incipient rupture from a productive portion. The heart chamber is preferably partitioned with a reinforced membrane which has a pressure receiving surface that defines part of the productive portion of the heart chamber. The peripheral base of the reinforced membrane may have an eccentric configuration.

This invention is directed to a partitioning device for separating a patient's heart chamber into a productive portion and a non-productive portion which is suitable for treating patients with heart disease, particularly congestive heart failure. The partitioning device has a reinforced membrane with outwardly biased members to help seal the periphery of the membrane against the wall of the patient's heart chamber. In one embodiment, the outwardly biased member is an expansive strand that extends between adjacent ribs of an expandable frame which reinforces the membrane. In another embodiment, the outwardly biased member is a hydrophilic body such as foam which swells upon contact with body fluid such as blood in the heart chamber. The reinforced membrane has a central hub with a distally extending support stem with a plurality of feet which extend radially from a centerline axis and preferably have ends that are aligned in a common plane. The ends of the pods which extend radially away from the centerline axis may be interconnected by flexible struts and/or webs.

This invention is directed to a device and method of using the device for partitioning a patient's heart chamber into a productive portion and a non-productive portion. The device is particularly suitable for treating patients with congestive heart failure. The device has an inflatable partitioning element which separates the productive and non-productive portions of the heart chamber and in some embodiments also has a supporting element, which may also be inflatable, extending between the inflatable partitioning element and the wall of the non-productive portion of the patient's heart chamber. The supporting element may have a non-traumatic distal end to engage the ventricular wall or a tissue penetrating anchoring element to secure the device to the patient's heart wall.

In an apparatus and method for detecting incipient heart failure of a patient. Impedance signals reflecting volume changes of the right ventricle and/or the right atrium of a heart of the patient are obtained. The impedance signals are processed to determine a first impedance parameter substantially reflecting a volume of the right ventricle, and a heart failure status is determined based on the first impedance parameter, wherein a decreasing first impedance parameter is determined to be an indication of a deterioration of the heart failure status.

An apparatus for treating a heart includes a housing member having a plurality of elongate channels defined therein and is movable between a first collapsed position and a second expanded position. A tissue attachment member is positioned in each channel. In one aspect, the apparatus is adapted for performing an anastomosis and includes a housing member having a plurality of elongate channels defined therein and which is movable between a fist collapsed position and a second expanded position. A surgical clip is positioned in each channel. A clip deployment mechanism projects the clips from their respective housings and a registration member approximates and aligns the first and second tubular structures. In a further aspect, helical barbs are movably affixed within sleeves formed on a sheetg of biocompatible material adapted for placement within a heart ventricle. Methods for treating a heart and reducing the volume of a heart ventricle are also provided. In a still further aspect, helical barbs provide attachment for patches for closure of a wound site or for suturing of a site needing closure. In yet another aspect of the invention, the helical barbs provide an attachment regine for implantable devices, as a well as a means to deliver medically efficacious materials to chosen sites with secure means. The helical device of the present invention further serves as a stent.

Partitioning devices that may be secured and sealed within a heart chamber for separating a patient's heart chamber into a productive portion and a non-productive portion are described herein. The partitioning devices described herein may include a reinforced membrane with outwardly biased members. The reinforced membrane may have a central hub with a distally extending support stem with a plurality of feet which extend radially from a centerline axis and preferably have ends that are aligned in a common plane. These devices may be secured within the heart chamber by sealing them to the wall of the heart chamber, for example, by inflating an inflatable element on the periphery of the device. The non-productive portion may be filled with a material, including occlusive materials. Sealing and/or filling the non-productive portion formed by the devices described herein may help prevent leakage from the non-productive region. Also described herein are systems including these devices and methods of using them, which may be suitable for treating patients with heart disease, particularly congestive heart failure.

A partitioning device for separating a patient's heart chamber into a productive portion and a non-productive portion which is suitable for treating patients with heart disease, particularly congestive heart failure. The partitioning device has a reinforced membrane with outwardly biased members to help seal the periphery of the membrane against the wall of the patient's heart chamber. In one embodiment, the outwardly biased member is an expansive strand that extends between adjacent ribs of an expandable frame which reinforces the membrane. In another embodiment, the outwardly biased member is a hydrophilic body such as foam which swells upon contact with body fluid such as blood in the heart chamber. The reinforced membrane has a central hub with a distally extending support stem with a plurality of feet which extend radially from a centerline axis and preferably have ends that are aligned in a common plane. The ends of the pods which extend radially away from the centerline axis may be interconnected by flexible struts and/or webs.

The invention discloses a preparation method of an injectable gel material of sodium alga acid-protein adhesive used for treating myocardial infarction, relating to injectable hydrogelin and a preparation method of the hydrogelin. The material and the method solve the technical problems of the existing injectable hydrogelin using calcium ion for crosslinking such as poor compatibility with organisms and undesirable mechanical property. The injectable gel material of sodium alga acid-protein adhesive used for treating myocardial infarction is made from the component sodium alga acid and the component protein adhesive that are mixed. The preparation method includes: adding sodium alga acid in water to oscillate with light avoidance on a table concentrator, thus generating partially oxidized sodium alga acid solution; adding glycol to the solution and placed on the table concentrator to oscillate, then adding sodium chloride to oscillate, dissolve and precipitate, dissolving the precipitate in water to attain collosol, and dialyzing and freeze-drying to obtain partially oxidized sodium alga acid; formulating the sodium alga acid solution to obtain sodium alga acid component; formulating gelatin or collagen to obtain protein adhesive component; and mixing the sodium alga acid component with the protein adhesive component for use. The injectable gel material can be used for treating myocardial infarction.

Provided is a method of treating or preventing a cardiomyopathy associated with activation of at least one kinase in the MAP kinase signaling pathway in heart tissue by providing to a subject an inhibitor of at least one kinase in the ERK signaling pathway or in the JNK signaling pathway, or both. In some embodiments, the cardiomyopathy is associated with one or more mutations in the LMNA gene, which encodes A-type nuclear lamins, or in the EMD gene, which encodes an inner nuclear membrane protein.

The present invention provides for methods and compositions for treating and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, functional analogue or a pharmaceutically effective salt thereof.

A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of the heart, an increase in ejection fraction, an increase in glucose oxidation or a decrease in fatty acid oxidation, as determined by conventional methods known in the art.

The invention discloses application of an emodin succinyl ester compound in preparation of a medicine for resisting myocardial ischemia and belongs to the technical field of medicines. The emodin succinyl ester compound has a structure shown as a formula I (R is C1 to C5 alkyl). Pharmacological experiments on rats and mice for experimenting myocardial infarction prove that the emodin succinyl ester compound has the advantages of remarkable myocardial ischemia resisting effect, good safety, simplicity and convenience for drug utilization, low raw material price and easiness for obtaining, and convenience for transportation and preservation. The emodin succinyl ester compound disclosed by the invention is used as a myocardial ischemia resisting drug and has a wide application prospect. The formula I is shown in the description.

The invention relates to the technical field of biomedical engineering and provides a use of a RyR2 protein or a RyR2 recombinant protein in preparation of an anti-heart failure drug. The RyR2 recombinant protein is a fragment or a mutant of a natural RyR2 protein, such as a SPRY1 structural domain protein, a P1 structural domain protein, a SPRY2 structural domain protein, a SPRY3 structural domain protein, a Handle structural domain protein, a HD1 structural domain protein, a HD2 structural domain protein, a central structural domain protein, an EF-hand structural domain protein, a U-type motif protein, a P2 structural domain protein, a P2 structural domain fragment protein 1, a P2 structural domain fragment protein 2 or a P2 mutant of the natural RyR2 protein. The exogenous RyR2 recombinant protein has a high expression level in normal small animal models and small animal disease models so that the left ventricular ejection fractions of the experimental animals are increased to different extents compared with the control group, the disease model animals are able to reduce the beta-adrenergic-induced ventricular tachyarrhythmia to varying degrees and the ventricular function of each treatment group is recovered to varying degrees.

The present invention provides for methods of treating and slowing the onset of heart failure. The inventors have determined that myosin binding to unphosphorylated Myosin Binding Protein C (MyBP-C) plays a key role in the diminution of cardiac contractile force and frequency in heart failure. The present invention provides peptide inhibitors of the MyBP-C/myosin interaction, thereby increasing both cardiac contractile force and frequency in the failing heart, as well as in patients not yet exhibiting frank heart failure.